Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

UV 1

Drug Profile

UV 1

Alternative Names: UV-1; UV1 synthetic peptide vaccine; UV1 vaccine; UV1-103

Latest Information Update: 26 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Norwegian Radium Hospital; Ultimovacs AS
  • Developer Arbeitsgemeinschaft Internistische Onkologie; AstraZeneca; Bristol-Myers Squibb; European Network of Gynaecological Oncological Trial Groups; Hellenic Cooperative Oncology Group; Nordic Society of Gynaecological - Clinical Trial Unit; North Eastern German Society of Gynaecological Oncology; Oslo University Hospital; Ultimovacs AS; Vestre Viken Hospital Trust; Working Group for Gynecological Oncology
  • Class Antineoplastics; Cancer vaccines; Immunotherapies; Peptide vaccines; Synthetic vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant melanoma; Malignant-mesothelioma
  • New Molecular Entity No

Highest Development Phases

  • Phase II Head and neck cancer; Malignant melanoma; Malignant-mesothelioma; Non-small cell lung cancer; Ovarian cancer
  • Phase I/II Prostate cancer

Most Recent Events

  • 21 Mar 2024 9412909 - added patent info and HEs (downloaded Annual report 2023 for reference)
  • 21 Mar 2024 Ultimovacs has patent pending for UV 1 in combination with an immune checkpoint inhibitor and anti-CTLA-4 and/or anti-PD(L)-1 antibodies in Europe, Japan, Australia and Canada
  • 21 Mar 2024 Ultimovacs has patent protection for UV 1 composition of matter in Europe, USA, Japan, Russia, South Korea, India, China and Hong Kong
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top